logo

Biotech Stocks Facing FDA Decision In May 2020

Drugs At The Altar
Drugs At The Altar

The ongoing COVID-19 pandemic has disrupted everyone's routine activities. Some pharma companies have paused enrollment or screening in their clinical trials while the FDA has canceled or postponed its AdComm meetings in light of the pandemic.

But that said, the regulatory agency hasn’t put off making a decision on drugs proposed for rare tumors and life-threatening diseases in this critical time.

Although the nation’s emphasis is on the need to combat COVID-19, patients with cancer and their unique needs continue to be a top priority for the FDA,” says Richard Pazdur, director of the FDA’s Oncology Center of Excellence.

Share